ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,765 companies indexed · Last updated: today
DirectoryAssociations & Interest GroupsNGOs & NPOsGenevaDrugs for Neglected Diseases initiative (DNDi)
Drugs for Neglected Diseases initiative (DNDi) Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The company's core activity is the development and provision of medical treatments, particularly for neglected tropical diseases (NTDs) and viral diseases, including pandemic and climate-related diseases. The company focuses on developing new treatments to improve accessibility and affordability for patients in low- and middle-income countries.

AI-generated
Offering

Products & services

Industry:NGOs & NPOsResearch & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Drugs for Neglected Diseases initiative (DNDi)

✓ Offered8
Drug development for neglected diseases
Development of life-saving therapies for neglected patients, from active ingredient research through translational research and clinical trials to registration and access.
Research and treatment access projects
A portfolio of more than 40 research and access projects, including initiatives to identify new chemical entities and to improve access to treatments.
Policy advocacy for open and collaborative R&D
Advocacy for public accountability, open and collaborative research, better priority-setting, coordination and sustainable funding in the biomedical R&D system.
Policy advocacy for cost transparency in R&D
Advocacy for transparency of R&D costs, accountability and fair medicine prices, so that innovations remain accessible and affordable.
Policy advocacy for access-friendly patent and licensing policy
Advocacy to ensure that intellectual property rights do not hinder access and the introduction of new treatments.
Global research networks and clinical platforms
Building and coordinating networks with clinicians, scientists, ministries of health, WHO, academia and civil society to strengthen clinical research capacity.
Capacity building for clinical research
Improving health infrastructure, renovating clinics and laboratories, providing equipment and materials, as well as continuous training of health personnel.
Research collaborations with industry, universities and non-profits
Collaborations with industry partners, universities, research centres, NGOs and health facilities to develop new medicines and to improve access to treatments.
Trust & reputation

ranQ Trust Score of Drugs for Neglected Diseases initiative (DNDi): 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Drugs for Neglected Diseases initiative (DNDi) has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Drugs for Neglected Diseases initiative (DNDi) scores 95.1 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.96.07%
Drugs for Neglected Diseases initiative (DNDi) scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Drugs for Neglected Diseases initiative (DNDi) scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Drugs for Neglected Diseases initiative (DNDi) reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Drugs for Neglected Diseases initiative (DNDi) has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Drugs for Neglected Diseases initiative (DNDi) in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Drugs for Neglected Diseases initiative (DNDi) by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Drugs for Neglected Diseases initiative (DNDi) to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Chemin Camille-VIDART 15
1202 Geneva

At a glance

Legal form
Foundation
UID
CHE-110.141.200
Founded
2003 · 23 years
Last commercial register change
June 5, 2026
Employees
101 to 500
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.97.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    GF
    GARDP Foundation
    Geneva
    GC
    Global Centre for the Responsibility to Protect (Geneva)
    Geneva
    NA
    NCD Alliance
    Geneva
    FE
    Fondation EspeRare
    Geneva
    NP
    Nonviolent Peaceforce International
    Geneva
    TB
    The BOLD Global Alliance for Women, Girls and Sport
    Geneva
    FI
    Franciscans International Association
    Geneva
    TG
    The Global Surgery Foundation
    Geneva